Advances in Chronic Obstructive Pulmonary Disease (COPD) Research Program
Medivir (Huddinge, Sweden) and one of China’s largest pharmaceutical companies, Jiangsu Hengrui Medicine Company (Shanghai), instigated a two year research collaboration in December 2003 to develop protease inhibitors against chronic obstructive pulmonary disease (COPD). Pivotal advances have been made and important milestones achieved in the project. Medivir and Hengrui have therefore elected to extend their research collaboration for developing drugs against COPD. The project is based on Medivir’s COPD protease inhibitor program, screening systems and enabling technologies, combined with